Six Percent Rise in Pradaxa Lawsuits, Consumers Suffering From Internal Bleeding

New court records reveal that the number of lawsuits alleging internal bleeding injury or death from taking dangerous drug Pradaxa has increased 6 percent since mid-October.

Cases stemming from the dangerous drug have been consolidated to a special federal court in Illinois. The latest court records from the Judicial Panel on Multidistrict Litigation shows that the number of cases filed has increased over 6 percent in one month, increasing from 1,643 to 1,748.

Pradaxa is a blood thinner that was approved by the Food and Drug Administration (FDA) in 2010. The defective drug is prescribed to patients with atrial fibrillation to prevent blood clots and stroke.

The Institute for Safe Medication Practices has warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from traditional blood thinner warfarin. This year, a European study discovered that patients taking anticoagulants like Pradaxa could be 55 percent more likely to suffer internal bleeding. A report ranked Pradaxa highest in the number of side effect complaints to the FDA in 2012, with 683 cases of internal bleeding.

I Have Been Harmed by Pradaxa and I Need an Experienced Lawyer

Drug manufacturers must exercise reasonable care in the labeling, manufacturing conditions and dissemination of vital information to medical doctors and pharmacists concerning the risks of their products. Colson Hicks Eidson has extensive experience representing victims in products liability actions who have suffered personal injury from taking prescription and over-the-counter drugs.

If you have been harmed by a dangerous or defective drug, call our firm today so we can hear your story. We want to know what you have gone through and experienced. Feel free to comment below or visit our Facebook page to share your story. We handle cases throughout the nation and around the globe.

Colson Hicks Eidson – Injury Attorneys



Tags: , ,

Leave a Reply

Your email address will not be published. Required fields are marked *